“Have you heard about the new findings from the MINDACT (EORTC 10041/BIG3-04) phase III trial? The findings reveal that the MammaPrint 70-gene signature can help guide chemotherapy decisions for invasive lobular carcinoma (ILC) patients.
Key findings:
- 16% of ILC cases are 70-gene high-risk with poor outcomes.
- Survival rates by 70-gene risk are similar for ILC and NST patients.
- No chemotherapy for high clinical, low genomic risk ILC patients should be considered.
- MammaPrint could facilitate chemotherapy decisions for patients diagnosed with ILC.
Discover how MammaPrint could transform treatment decisions for ILC patients.
Authors: O. Metzger Filho, et al.
More posts featuring EORTC.